AstraZeneca PLC (AZN) Stock
NASDAQAZN has an Alpha Score of 41 out of 100 (weak), computed on Nov 21, 2026 from 3 of 4 sub-scores. 19 members of Congress disclosed 36 trades in AZN since 2014: 18 purchases and 17 sales, most recently Alan Armstrong (purchase, Mar 31, 2026). Its trailing P/E ratio is 26.0 and its net margin 17.7% (key statistics as of Nov 12, 2026).
What is AZN's Alpha Score?
How it works →Alpha Score of 41 reflects weak overall profile with weak momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 21, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded AstraZeneca PLC (AZN)?
Most recent: Alan Armstrong (purchase, Mar 31, 2026); records start Apr 25, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-31 | purchase | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-30 | purchase | $15k – $50k |
| Gil Cisneros D-CA · House | 2025-12-18 | purchase | $1k – $15k |
| Julia Letlow R-LA · House | 2025-12-08 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-11-19 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.
Every member of Congress who traded AZN, with filing lags →Are AstraZeneca PLC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 8, 26 | Sharma Mani | See Remarks | BUY | 20.233 | $3K |
SEC Form 4 filings as of Nov 20, 2026
See cluster-buy signals across all tickers →What are AZN's key statistics?
Key statistics as of Nov 12, 2026
How does AZN's valuation compare with the Healthcare sector?
| Metric | AZN | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 26.0 | 29.1 | 147 |
| Net margin | 17.68% | 3.59% | 223 |
| Return on equity | 22.28% | 3.41% | 255 |
| Dividend yield (payers) | 2.30% | 1.37% | 61 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.
AZN price chart
Powered by TradingViewWhat does AstraZeneca PLC do?
AstraZeneca PLC American Depositary Shares represent ownership in AstraZeneca PLC, a multinational biopharmaceutical company headquartered in Cambridge, United Kingdom. The company focuses on the discovery, development, manufacture, and commercialization of prescription medicines across key therapeutic areas. Oncology constitutes its largest segment, featuring products like Tagrisso, Imfinzi, Calquence, Enhertu, and Truqap. Other core areas include cardiovascular, renal, and metabolic medicines such as Farxiga and Brilinta; rare disease therapies like Ultomiris and Soliris; and respiratory and immunology treatments including Symbicort, Fasenra, and Breztri. AstraZeneca PLC also offers vaccines and immune therapies. It serves primary and specialty care physicians globally through distributors and local offices, with significant presence in the United States, Europe, and Asia. This structure positions AstraZeneca PLC as a major player in the global pharmaceutical industry, addressing diverse medical needs in oncology, rare diseases, and chronic conditions.